Last reviewed · How we verify

Ultra-Long GnRH Agonists

University of Palermo · FDA-approved active Small molecule

Ultra-Long GnRH Agonists is a GnRH agonist Small molecule drug developed by University of Palermo. It is currently FDA-approved for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids.

Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release.

Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release. Used for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids.

At a glance

Generic nameUltra-Long GnRH Agonists
SponsorUniversity of Palermo
Drug classGnRH agonist
TargetGnRH receptor
ModalitySmall molecule
Therapeutic areaOncology; Endocrinology
PhaseFDA-approved

Mechanism of action

These agents bind to GnRH receptors and provide extended pharmacological activity through modified formulations or delivery systems, resulting in continuous suppression of the hypothalamic-pituitary-gonadal axis. This leads to sustained reduction in sex hormone production (testosterone and estrogen), with effects lasting weeks to months per dose. The ultra-long duration distinguishes them from conventional GnRH agonists by reducing dosing frequency and improving patient compliance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ultra-Long GnRH Agonists

What is Ultra-Long GnRH Agonists?

Ultra-Long GnRH Agonists is a GnRH agonist drug developed by University of Palermo, indicated for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids.

How does Ultra-Long GnRH Agonists work?

Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release.

What is Ultra-Long GnRH Agonists used for?

Ultra-Long GnRH Agonists is indicated for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids, Precocious puberty.

Who makes Ultra-Long GnRH Agonists?

Ultra-Long GnRH Agonists is developed and marketed by University of Palermo (see full University of Palermo pipeline at /company/university-of-palermo).

What drug class is Ultra-Long GnRH Agonists in?

Ultra-Long GnRH Agonists belongs to the GnRH agonist class. See all GnRH agonist drugs at /class/gnrh-agonist.

What development phase is Ultra-Long GnRH Agonists in?

Ultra-Long GnRH Agonists is FDA-approved (marketed).

What are the side effects of Ultra-Long GnRH Agonists?

Common side effects of Ultra-Long GnRH Agonists include Hot flashes, Decreased libido, Erectile dysfunction, Injection site reactions, Headache, Fatigue.

What does Ultra-Long GnRH Agonists target?

Ultra-Long GnRH Agonists targets GnRH receptor and is a GnRH agonist.

Related